In recent years, progress has been made in improving patient outcomes and extending the survival of patients with BRAF‐mutant cancers relative to standard‐of‐care chemotherapeutic approaches using a targeted approach towards inhibition of the kinase activity of BRAF V600 mutants.6, 7. The gene discussed is BRAF; the disease is cancer.